| scholarly article | Q13442814 |
| P50 | author | Andrew R. Lloyd | Q44958229 |
| Kimberly Page | Q51846987 | ||
| Joseph S Doyle | Q67211552 | ||
| P2093 | author name string | M P Manns | |
| G J Dore | |||
| J Grebely | |||
| M E Hellard | |||
| A Y Kim | |||
| G Matthews | |||
| B H McGovern | |||
| M D Morris | |||
| H Wedemeyer | |||
| InC3 Study Group | |||
| J Bruneau | |||
| K Deterding | |||
| T M Rice | |||
| T Spelman | |||
| R Sacks-Davis | |||
| P2860 | cites work | A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus | Q24307721 |
| Genetic variation in IL28B and spontaneous clearance of hepatitis C virus | Q24596340 | ||
| Testing Strategy To Identify Cases of Acute Hepatitis C Virus (HCV) Infection and To Project HCV Incidence Rates | Q27485369 | ||
| Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection | Q27490862 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study | Q28269827 | ||
| Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients | Q28274666 | ||
| Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus | Q28279955 | ||
| Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| A review of the treatment of chronic hepatitis C virus infection in cirrhosis | Q33394104 | ||
| Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection | Q33650138 | ||
| Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C | Q33955516 | ||
| Prospective evaluation of community-acquired acute-phase hepatitis C virus infection | Q33986385 | ||
| Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection | Q34164063 | ||
| Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients | Q34333821 | ||
| Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. | Q34648995 | ||
| Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection | Q34714349 | ||
| Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. | Q34983860 | ||
| Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies | Q36346436 | ||
| Current and emerging antiviral treatments for hepatitis C infection | Q36729900 | ||
| Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis | Q37161958 | ||
| Treatment predictors of a sustained virologic response in hepatitis B and C. | Q37248066 | ||
| Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study. | Q37460833 | ||
| The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection | Q37678136 | ||
| Treatment of acute HCV infection | Q37855530 | ||
| Epidemiology and natural history of HCV infection. | Q38118578 | ||
| Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study | Q40355356 | ||
| Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin | Q42232261 | ||
| High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection | Q42985356 | ||
| IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. | Q42987167 | ||
| Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial | Q42990460 | ||
| Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection | Q42993901 | ||
| An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response | Q42998430 | ||
| Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. | Q43001836 | ||
| Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? | Q43036063 | ||
| Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load | Q43041574 | ||
| Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance | Q43042132 | ||
| A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice | Q43625075 | ||
| EASL Clinical Practice Guidelines: management of hepatitis C virus infection | Q86939378 | ||
| P433 | issue | 12 | |
| P921 | main subject | Hepatitis C virus | Q708693 |
| collaboration | Q1145523 | ||
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 1020-1032 | |
| P577 | publication date | 2015-06-22 | |
| P1433 | published in | Journal of Viral Hepatitis | Q15749962 |
| P1476 | title | Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort | |
| P478 | volume | 22 |
| Q60044043 | Changing the odds: motives for and barriers to reducing HCV-related sexual risk behaviour among HIV-infected MSM previously infected with HCV |
| Q40229182 | HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C. |
| Q26752471 | KASL clinical practice guidelines: management of hepatitis C |
| Q40393165 | Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study |
| Q40248569 | Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial |
| Q49853233 | Treatment of acute hepatitis C: recommendations from an expert panel of the Italian Society of Infectious and Tropical Diseases. |
Search more.